In a government letter published on July 27, the National Institute of Health and eight other national institutes wrote that they aim “to promote mechanistic research of therapeutic benefits of minor cannabinoids and terpenes in the cannabis plant.”
Published in the Journal of Clinical Psychiatry, the study involved 31 people aged between 12 and 25 who had been diagnosed with an anxiety disorder. All were given CBD capsules to take daily over twelve weeks.
Published in the journal JAMA Otolaryngology–Head & Neck Surgery, the study used data collected by the National Health and Nutrition Examination Survey (NHANES) to assess the association between cannabis use frequency and reports of sinonasal symptoms.
High-potency cannabis use is associated with an increased risk of experiencing psychosis and cannabis use disorder (CUD) compared to low-potency products, according to the first systematic review on the topic.
Adolescents who use tobacco e-cigarettes are significantly more likely to report also using cannabis one year later, according to a new study by researchers at the University of Alabama at Birmingham and the University of Michigan.
The bill is expected to pass through the Senate and land on the president’s desk for his approval.
Three cannabis cultivation companies and one testing lab are facing a class action lawsuit in Arkansas. The allegation? That all four conspired to defraud medical cannabis patients by inflating cannabis potency testing results.
Any cannabis lab analyst that has a unique method for identifying and quantifying pesticides in dried cannabis samples has been invited to submit their technique to AOAC International.